First Complement-Inhibition Study in ITP Is Promising

]]>(MedPage Today) -- Up to 20% of patients with immune thrombocytopenia (ITP) have inadequate responses to current therapy and remain at risk of life-threatening bleeds. In a study presented at the 2019 American Society of Hematology annual meeting...